Share >  
Share
Share on Tumblr

Glenn Saldanha

News »

   latest by relevance
Launches in FY13 to boost growth in Indian market: Glenmark
May 09, 2012 at 11:42 | Source: CNBC-TV18
Aided by malarone and cutivate generic, the US business of Glenmark Pharma saw recovery in the fourth quarter of FY12. In an interview with CNBC-TV18, Glenn Saldanha, MD & CEO of Glenmark said, the company expects its domestic market to outperform industry in FY13.
Profit down 35%, but topline at record Rs 1055 cr: Glenmark
Nov 09, 2011 at 15:00 | Source: CNBC-TV18
Glenn Saldanha, managing director and chief executive officer of Glenmark joins CNBC-TV18 to talk about the company's Q2 performance and highlight the way forward.
Glenmark's R&D gamble
Sep 22, 2011 at 12:35 | Source: Forbes India
With Indian pharma companies willing to cash out, is Glenn Saldanha Indias best bet for a home-grown drug?
Glenmark Pharma sees its India business growing at 23-24%
May 11, 2011 at 10:46 | Source: CNBC-TV18
Glenn Saldanha, managing director and CEO of Glenmark Pharmaceuticals, in an interview with CNBC-TV18's Udayan Mukherjee and Mitali Mukherjee, said that its business in India is growing at 23-24%, while its business in US is expected to grow 25% in FY12.
Glenmark announces discovery of new oncology molecule
Mar 31, 2011 at 11:26 | Source: Reuters
Glenmark Pharmaceuticals on Thursday announced the discovery of a new molecule for oncology treatment and said it would file an application for phase-I trials in the fourth quarter of FY12.
Glenmark confident of US growth despite Tarka issue
Mar 14, 2011 at 11:40 | Source: CNBC-TV18
In an interview with CNBC-TV18, Glenn Saldanha, managing director and chief executive officer of Glenmark Pharmaceuticals said,"Tarka is not a major contributor any more to the topline for the US business."

Videos »
Launches in FY13 to boost growth in Indian market: Glenmark
Profit down 35%, but topline at record Rs 1055 cr: Glenmark
Glenmark Pharma sees its India business growing at 23-24%
Glenmark confident of US growth despite Tarka issue
No plans to list generics biz as of now: Glenmark
more »

Photos »

  /  
Interact & exchange stock tips & market info »

StockChamp0
1

Platinum Member

617 Followers

Twilight Litaka  

Securities Vice President, Institutional Research Ranjit Kapadia said...

5.10 PM Nov 23rd 2011

Web Messenger

Platinum Member

108212 Followers

Glenmark  

-valued due to rupee depreciation, Mr Glenn Saldanha, Ch...

11.00 PM Feb 3rd

Related News »
Search Results glenn saldanha
Glenmark Pharmaceuticals is set to enter the final stage of clinical trials for its new drug, Revamilast, across several countries this year. It is meant for treatment of inflammatory disorders like asthma and rheumatoid arthritis. Glenmark may soon seek ...
May 24, 2012 at 19:32 | Source: Business Standard
Glenmark close to final clinical trials for asthma, arthritis drugs
The company intends to initiate Phase-III trials for at least one indication by the end of FY13,” chairman and managing director Glenn Saldanha told Business Standard. The current market for rheumatoid arthritis is estimated at around $26 billion and the ...
May 24, 2012 at 19:39 | Source: Business Standard
Glenmark sees 22-25% sales growth, no acquisitions in FY13
Glenn Saldanha, the company's chairman and MD said virtually every geography (except central and eastern Europe) that it operates in is profitable at the EBITDA level. Among key business segments, revenue from Glenmark's generics business rose ...
May 9, 2012 at 06:28 | Source: MoneyControl.com
Piramal's Quest for a Blockbuster Drug
However, this is cash expense and doesn’t include the opportunity cost,” says Glenn Saldanha, chairman and MD of Glenmark. The Piramals’ strategy has been to look for reverse brain gain (15 percent of nearly 400 R&D folks have returned from overseas ...
May 28, 2012 at 03:28 | Source: forbesindia.com

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window